Investigating a potential treatment target for acute myeloid leukemia
The histone demethylase JMJD1C in human Acute Myeloid Leukemia
['FUNDING_R37'] · J. CRAIG VENTER INSTITUTE, INC. · NIH-11176820
This study is looking at how a specific protein called JMJD1C affects acute myeloid leukemia (AML) and whether combining treatments that target this protein with drugs that block the RAS pathway can help improve outcomes for patients, especially those with RAS mutations.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | J. CRAIG VENTER INSTITUTE, INC. (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11176820 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of JMJD1C, a histone demethylase, in acute myeloid leukemia (AML). The study aims to explore how targeting JMJD1C, particularly in combination with inhibitors of the RAS signaling pathway, can improve treatment outcomes for patients with AML, especially those with RAS mutations. Researchers will use mouse models and xenograft models to test the effectiveness of this combined therapy and investigate the underlying mechanisms of resistance to JMJD1C loss. The goal is to develop a more effective treatment strategy for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with RAS mutations.
Not a fit: Patients with acute myeloid leukemia who do not have RAS mutations may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in leukemia, suggesting that this approach may be effective.
Where this research is happening
LA JOLLA, UNITED STATES
- J. CRAIG VENTER INSTITUTE, INC. — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, NAN — J. CRAIG VENTER INSTITUTE, INC.
- Study coordinator: ZHU, NAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.